GlassScriptPhysician profile
May A Bonnin
NPI 1295204204
$3,462.30
in general payments reported to CMS, 2019-2025
21 companies · $894 in 2025
The $894 reported for 2025 was more than what 95% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $397 · 2022: $441 · 2023: $843 · 2024: $887 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,624.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $340.14 | 2022-2025 | Mounjaro |
| Novo Nordisk INC | $310.08 | 2022-2025 | Ozempic, Wegovy |
| Abiomed | $271.96 | 2024 | Impella |
| Amgen INC. | $249.74 | 2023-2024 | Evenity |
| Galderma Laboratories, L.P. | $215.99 | 2021-2025 | |
| Nevro Corp. | $208.95 | 2023 | Senza |
| Abbvie INC. | $199.80 | 2023-2025 | |
| Allergan, INC. | $193.27 | 2021-2022 | |
| Corcept Therapeutics | $139.37 | 2025 | Korlym |
| Viiv Healthcare Company | $125.03 | 2025 | Apretude |
| Vertex Pharmaceuticals Incorporated | $124.99 | 2025 | |
| Glaxosmithkline, LLC. | $124.70 | 2022 | |
| Dexcom, INC. | $124.06 | 2023 | Dexcom G7 Gss (161) |
| Axsome Therapeutics, INC. | $123.95 | 2023 | Auvelity |
| Incyte Corporation | $114.91 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $113.60 | 2022-2025 | |
| Smith+Nephew, INC. | $104.85 | 2023 | Pico, Allevyn Heel 10.5cm X 13.5cm Ctn 5, Acticoat 4" X 4" |
| Daiichi Sankyo INC. | $103.88 | 2024 | Injectafer |
| Revance Therapeutics, INC. | $98.50 | 2024-2025 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.89 | 2021 | |
| Antares Pharma, INC. | $82.64 | 2023 | Xyosted, Tlando |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw May Bonnin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.